Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
Share this article
Novigenix SA, a Swiss Health Valley leader in immunotranscriptomic diagnostics, announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence.
A Strategic Separation to Unlock Two High-Growth Markets
The new AI spin-out separates Novigenix’s colorectal cancer (CRC) screening business from its rapidly growing AI-driven biopharma and precision medicine platform, allowing each entity to pursue focused go-to-market strategies, tailored capital structures, and distinct partnership pathways.
Novigenix SA will continue advancing its CRC screening portfolio, including the Colox® and ColoxNGS® assays, distributed through Diagnosuite™ and clinical laboratory partners.
Novigenix AI will exclusively commercialize the LITOSeek® platform for biopharma, biotech, and precision medicine clinical applications globally. The LITOSeek® platform analyzes blood RNA to generate predictive and mechanistic insights that guide therapy development, patient stratification, and clinical decision-making.
“The tumor is only half the story. To deliver truly personalised medicine, we must understand how the patient’s immune system responds to disease and therapy. Spinning out Novigenix AI enables laser-focused investment, faster market penetration, and greater value creation for our shareholders and biopharma partners. This is the beginning of a new era in immune intelligence,” says Brian B. Hashemi, Ph.D., MBA, CEO & Chairman, Novigenix AI.
➡️ Source: Press Release | 📸 ©Novigenix